Macrophage-activation syndrome

WikiDoc Resources for Macrophage-activation syndrome
Articles
Most recent articles on Macrophage-activation syndrome Most cited articles on Macrophage-activation syndrome Review articles on Macrophage-activation syndrome Articles on Macrophage-activation syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Macrophage-activation syndrome Images of Macrophage-activation syndrome Photos of Macrophage-activation syndrome Podcasts & MP3s on Macrophage-activation syndrome Videos on Macrophage-activation syndrome
Evidence Based Medicine
Cochrane Collaboration on Macrophage-activation syndrome Bandolier on Macrophage-activation syndrome TRIP on Macrophage-activation syndrome
Clinical Trials
Ongoing Trials on Macrophage-activation syndrome at Clinical Trials.gov Trial results on Macrophage-activation syndrome Clinical Trials on Macrophage-activation syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Macrophage-activation syndrome NICE Guidance on Macrophage-activation syndrome NHS PRODIGY Guidance FDA on Macrophage-activation syndrome CDC on Macrophage-activation syndrome
Books
Books on Macrophage-activation syndrome
News
Macrophage-activation syndrome in the news Be alerted to news on Macrophage-activation syndrome News trends on Macrophage-activation syndrome
Commentary
Blogs on Macrophage-activation syndrome
Definitions
Definitions of Macrophage-activation syndrome
Patient Resources / Community
Patient resources on Macrophage-activation syndrome Discussion groups on Macrophage-activation syndrome Patient Handouts on Macrophage-activation syndrome Directions to Hospitals Treating Macrophage-activation syndrome Risk calculators and risk factors for Macrophage-activation syndrome
Healthcare Provider Resources
Symptoms of Macrophage-activation syndrome Causes & Risk Factors for Macrophage-activation syndrome Diagnostic studies for Macrophage-activation syndrome Treatment of Macrophage-activation syndrome
Continuing Medical Education (CME)
CME Programs on Macrophage-activation syndrome
International
Macrophage-activation syndrome en Espanol Macrophage-activation syndrome en Francais
Business
Macrophage-activation syndrome in the Marketplace Patents on Macrophage-activation syndrome
Experimental / Informatics
List of terms related to Macrophage-activation syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: MAS

Overview

Macrophage-activation syndrome (MAS) is a severe, potentially life-threatening, complication of several chronic rheumatic diseases of childhood. It occurs most commonly with systemic-onset juvenile idiopathic arthritis (SoJIA), which is also known as Still's disease. In addition, MAS has been described in association with systemic lupus erythematosus (SLE), Kawasaki disease, and adult-onset Still's disease. It is thought to be closely related and pathophysiologically very similar to reactive (secondary) hemophagocytic lymphohistiocytosis (HLH). The incidence of MAS is unknown as there is a wide spectrum of clinical manifestations, and episodes may remain unrecognized.

Diagnosis

The hallmark clinical and laboratory features include high fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, liver dysfunction, disseminated intravascular coagulation, hypofibrinogenemia, hyperferritinemia, and hypertriglyceridemia. Despite marked systemic inflammation, the erythrocyte sedimentation rate (ESR) is paradoxically depressed, caused by low fibrinogen levels. The low ESR helps to distinguish the disorder from a flare of the underlying rheumatic disorder, in which case the ESR is usually elevated. A bone marrow biopsy or aspirate usually shows hemophagocytosis.

The diagnosis relies on the findings outlined above. In addition, other specific markers of macrophage activation (e.g. soluble CD63), and lymphocyte activation (e.g. soluble IL-2 receptor) can be helpful. NK cell function analysis may show depressed NK function, or, flow cytometry may show a depressed NK cell population.

Pathophysiology

In many cases a trigger is identified, often a viral infection, or a medication. There is uncontrolled activation and proliferation of macrophages, and T lymphocytes, with a marked increase in circulating cytokines, such as IFN-gamma, and GM-CSF. The underlying causative event is unclear, and is the subject of ongoing research. In many cases of MAS, a decreased natural killer cell (NK-cell) function is found.

Treatment

The best treatment for MAS has not been firmly established. Most commonly used treatments include high-dose glucocorticoids, and cyclosporine. In refractory cases treatment regimens are used similar to that in HLH.